William Blair Initiates Outperform Coverage on Zura Bio, Citing Strong Potential for Tibulizumab
William Blair cites strong upside potential for lead candidate tibulizumab in hidradenitis suppurativa and systemic sclerosis.
/ 2 items
William Blair cites strong upside potential for lead candidate tibulizumab in hidradenitis suppurativa and systemic sclerosis.
Wedbush gives Zura Bio an Outperform rating and $15 target, highlighting upcoming clinical catalysts and potential stock growth through 2026.